Envista (NYSE:NVST) Releases Quarterly Earnings Results

Envista (NYSE:NVST) released its quarterly earnings results on Wednesday. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04, FiscalAI reports. The company had revenue of $691.50 million for the quarter, compared to analysts’ expectations of $688.74 million. Envista had a net margin of 3.33% and a return on equity of 7.88%. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period last year, the company earned $0.32 EPS.

Here are the key takeaways from Envista’s conference call:

• Envista reported 2.7% core sales growth, with adjusted EBITDA up 9% and adjusted EPS up 25%; gross and EBITDA margins expanded 20 and 80 basis points, respectively. Free cash flow conversion was 97%, and net leverage remained low at 0.6x.
• The company raised its 2026 outlook, now expecting 3.75%–4.25% core sales growth, 12.5%–14% adjusted EBITDA growth, and adjusted EPS of $1.54–$1.58. Management said the fourth-quarter outlook implies slightly negative core growth, partly reflecting four fewer selling days and continued macro uncertainty.
• China sales fell at a low-double-digit rate as orthodontics customers destocked ahead of VBP; management expects the process to bring substantial price reductions, including about 50% for orthodontics and 10%–15% for implants. It expects VBP to support volume and share gains, but acknowledged margin pressure in China.
• Spark grew at a high-single-digit rate, diagnostics and implants each grew mid-single digits, and Envista said it continued to gain share in diagnostics. Management highlighted a strong new-product pipeline and said broader commercialization of recent launches will be a key growth priority for 2027.

Envista Trading Up 9.8%

Envista stock traded up $2.44 during midday trading on Wednesday, reaching $27.21. The stock had a trading volume of 6,113,924 shares, compared to its average volume of 3,135,394. Envista has a twelve month low of $18.77 and a twelve month high of $30.42. The stock has a market capitalization of $4.37 billion, a PE ratio of 46.91, a price-to-earnings-growth ratio of 1.26 and a beta of 0.94. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43. The stock’s 50-day simple moving average is $24.49 and its 200 day simple moving average is $25.74.

Wall Street Analyst Weigh In

NVST has been the subject of a number of analyst reports. Leerink Partners cut their price objective on shares of Envista from $35.00 to $32.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. UBS Group decreased their target price on shares of Envista from $30.00 to $27.00 and set a “neutral” rating on the stock in a research report on Friday, September 18th. Needham & Company LLC restated a “hold” rating on shares of Envista in a research report on Friday, September 18th. Mizuho set a $29.00 target price on shares of Envista in a research note on Thursday, August 6th. Finally, Piper Sandler cut their price target on Envista from $28.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 9th. Six equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.86.

Insider Transactions at Envista

In other Envista news, SVP Mischa Reis sold 8,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the sale, the senior vice president owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. The trade was a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.99% of the company’s stock.

About Envista

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.